Katie Albert, MD

Katie Albert, MD

Cancer and Blood Disorders Center, Neuroblastoma Program, Bone Tumors and Soft Tissue Tumors, I-131-MIBG Therapy, Solid Tumors Oncology, Immunotherapy Program

On staff since May 2016

Children's Title: Attending Physician, Cancer and Blood Disorders Center

Academic Title: Associate Professor

Research Center: Ben Towne Center for Childhood Cancer Research

"My overarching career goal is to improve the outcomes and quality of life for pediatric and young adult cancer patients, with a focus on those with musculoskeletal tumors (sarcomas) and other high-risk solid tumors. "

  • Patient Testimonials

    • Monisha Bellevue, WA 08.09.23

      Before I met Dr. Albert, I was in hospice care with relapsed, metastatic cancer that had not responded to existing therapies. While on hospice, I found Dr. Albert’s CAR T-cell clinical trial, which was open to young adults like myself with relapsed pediatric solid tumors. I came to Seattle Children’s because of Dr. Albert’s clinical trial, but I’ve stayed here because of Dr. Albert herself - she is truly one of a kind. In addition to pioneering the research that could change my outcome, she also has excellent judgment about what treatments to pursue and is tenacious on behalf of her patients. One moment in particular stands out the most: right after I became Dr. Albert’s patient, my main tumor had grown so large that it was about to close off my airway. There was no clear way to resolve the issue because my tumor was in a difficult location and was not fully resectable. But in just 24 hours, Dr. Albert had created a solution for me. She collaborated with a general surgeon and they developed a plan to debulk the tumor and preserve my airway. In addition to this surgery and the clinical trial, Dr. Albert has also come up with unique chemotherapy options that I didn’t have access to elsewhere. Throughout all of this treatment, she has always been there for me with great compassion and she treats me like a true partner when it comes to treatment decision-making. She always answers my questions patiently and in detail so that I can make the best decisions for myself. Had it not been for Dr. Albert’s novel research and expert medical care, I would not be here right now – and for that my family and I couldn’t be more grateful.

    Recommend Katie Albert, MD

  • Awards and Honors

    Award Name Award Description Awarded By Award Date
    Seattle Met's 2022 Top Doctors Award Seattle Met 2022

  • Publications

    Book Chapters

    • Albert CM and Pollack SM (Trent JC, Rosenberg AE, Pollack R, Delaney TF, eds)
      Immunotherapy for Sarcoma
      Sarcomas: Evidence-Based Diagnosis and Management, 2020 : 365-386
    • Albert CM (Arcara K and Tschudy M, eds)
      Oncology
      The Harriet Lane Handbook, 19th edition, 2011 June

    Other Publications

    • Vitanza NA, Johnson AJ, Wilson AL, Brown C, Yokoyama JK, Künkele A, Chang CA, Rawlings-Rhea S, Huang W, Seidel K, Albert CM, Pinto N, Gust J, Finn LS, Ojemann JG, Wright J, Orentas RJ, Baldwin M, Gardner RA, Jensen MC, Park JR
      Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis.
      34253928 Nature medicine, 2021 Jul 12
    • Parsons E, Albert C, Forouhar M, Kunz A, Sainato R
      Recurrent Severe Staphylococcus epidermidis Urinary Tract Infections in a 7-Year-Old Boy.
      34100657 Clinical pediatrics, 2021 July : 60(8)346-349
    • Wenger TL, Bly RA, Wu N, Albert CM, Park J, Shieh J, Chenbhanich J, Heike CL, Adam MP, Chang I, Sun A, Miller DE, Beck AE, Gupta D, Boos MD, Zackai EH, Everman D, Ganapathi S, Wilson M, Christodoulou J, Zarate YA, Curry C, Li D, Guimier A, Amiel J, Hakonarson H, Webster R, Bhoj EJ, Perkins JA, Dahl JP, Dobyns WB
      Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy.
      32500973 American journal of medical genetics. Part A, 2020 July : 182(7)1576-1591
    • Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, van Tilburg CM, Nagasubramanian R, Berlin JD, Federman N, Mascarenhas L, Geoerger B, Dowlati A, Pappo AS, Bielack S, Doz F, McDermott R, Patel JD, Schilder RJ, Tahara M, Pfister SM, Witt O, Ladanyi M, Rudzinski ER, Nanda S, Childs BH, Laetsch TW, Hyman DM, Drilon A
      Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
      32105622 The Lancet. Oncology, 2020 April : 21(4)531-540 PMCID:PMC7497841
    • Davis JL, Lockwood CM, Stohr B, Boecking C, Al-Ibraheemi A, DuBois SG, Vargas SO, Black JO, Cox MC, Luquette M, Turpin B, Szabo S, Laetsch TW, Albert CM, Parham DM, Hawkins DS, Rudzinski ER
      Expanding the Spectrum of Pediatric NTRK-rearranged Mesenchymal Tumors.
      30585824 The American journal of surgical pathology, 2019 April : 43(4)435-445
    • Crumm CE, Crotty EE, Albert CM, Blair AB, Otjen JP, Feldman KW
      Atraumatic Spinal Epidural Hematoma as Initial Presentation of Hemophilia A in an Infant.
      30870339 Pediatric emergency care, 2019 Mar 12
    • Albert CM, Davis JL, Federman N, Casanova M, Laetsch TW
      TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening.
      30592640 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019 Feb 20 : 37(6)513-524
    • Baheti AD, Chapman T, Rudzinski E, Albert CM, Stanescu AL
      Diagnosis, histopathologic correlation and management of hepatoblastoma: What the radiologist needs to know.
      30172849 Clinical imaging, 2018 Nov. : 52273-279
    • DuBois SG, Laetsch TW, Federman N, Turpin BK, Albert CM, Nagasubramanian R, Anderson ME, Davis JL, Qamoos HE, Reynolds ME, Cruickshank S, Cox MC, Hawkins DS, Mascarenhas L, Pappo AS
      The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
      30204247 Cancer, 2018 Nov 1 : 124(21)4241-4247 PMCID:PMC6263791
    • Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, Nagasubramanian R, Davis JL, Rudzinski E, Feraco AM, Tuch BB, Ebata KT, Reynolds M, Smith S, Cruickshank S, Cox MC, Pappo AS, Hawkins DS
      Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
      29606586 The Lancet. Oncology, 2018 May : 19(5)705-714 PMCID:PMC5949072
    • Ronsley R, Rassekh SR, Shen Y, Lee AF, Jantzen C, Halparin J, Albert C, Hawkins DS, Amed S, Rothstein R, Mungall AJ, Dix D, Blair G, Nadel H, Jones SJM, Laskin J, Marra MA, J Deyell R
      Application of genomics to identify therapeutic targets in recurrent pediatric papillary thyroid carcinoma.
      29610391 Cold Spring Harbor molecular case studies, 2018 April : 4(2) PMCID:PMC5880264
    • Davis JL, Lockwood CM, Albert CM, Tsuchiya K, Hawkins DS, Rudzinski ER
      Infantile NTRK-associated Mesenchymal Tumors.
      28683589 Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society, 2018 Jan. : 21(1)68-78
    • Hayashi M, Baker A, Goldstein SD, Albert CM, Jackson KW, McCarty G, Kahlert UD, Loeb DM
      Inhibition of porcupine prolongs metastasis free survival in a mouse xenograft model of Ewing sarcoma.
      29108227 Oncotarget, 2017 Oct 3 : 8(45)78265-78276 PMCID:PMC5667961
    • Hayashi M, Zhu P, McCarty G, Meyer CF, Pratilas CA, Levin A, Morris CD, Albert CM, Jackson KW, Tang CM, Loeb DM
      Size-based detection of sarcoma circulating tumor cells and cell clusters.
      29108279 Oncotarget, 2017 Oct 3 : 8(45)78965-78977 PMCID:PMC5668012
    • Hayashi M, Chu D, Meyer CF, Llosa NJ, McCarty G, Morris CD, Levin AS, Wolinsky JP, Albert CM, Steppan DA, Park BH, Loeb DM
      Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA.
      27351911 Cancer, 2016 Oct. : 122(19)3015-23 PMCID:PMC5102400
    • Goldstein SD, Hayashi M, Albert CM, Jackson KW, Loeb DM
      An orthotopic xenograft model with survival hindlimb amputation allows investigation of the effect of tumor microenvironment on sarcoma metastasis.
      26278104 Clinical & experimental metastasis, 2015 Oct. : 32(7)703-15
    • Huang X, Park H, Greene J, Pao J, Mulvey E, Zhou SX, Albert CM, Moy F, Sachdev D, Yee D, Rader C, Hamby CV, Loeb DM, Cairo MS, Zhou X
      IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas.
      26173023 PloS one, 2015 : 10(7)e0133152 PMCID:PMC4501840
    • Dean JB, Hayashi SS, Albert CM, King AA, Karzon R, Hayashi RJ
      Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens.
      18376265 Journal of pediatric hematology/oncology, 2008 Feb. : 30(2)130-4
    • Albert CM and Pollack SM
      Immunotherapy for Synovial Sarcoma
      AIMS Medical Science, 2019 : 6(3)191-200

  • Research Funding

    Grant Title Grantor Amount Award Date
    Pediatric Cancer Data Commons St. Baldrick’s Foundation Jul 1, 2019 - Jun 30, 2022
    Clinical Research Scholars Program Seattle Children's Research Institute Oct 1, 2018 - Sep 30, 2020

Overview

Board Certification(s)

Pediatric Hematology-Oncology

Medical/Professional School

George Washington University, Washington, DC

Residency

Johns Hopkins University School of Medicine, Baltimore, MD

Fellowship

Johns Hopkins University School of Medicine, Baltimore, MD
National Cancer Institute, Asuncion, Para

Clinical Interests

Musculoskeletal tumors (sarcomas), pediatric solid tumors, adolescent and young adult oncology

Research Description

Molecular targets in sarcomas, immunotherapy for pediatric solid tumors

 

Research Focus Area

Novel Therapeutics